Loading company…
Barcelona biotech developing first-in-class antibody drug conjugates for advanced cancers resistant to existing treatments.
Founded in 2019 and based in Barcelona, Spain, Ona Therapeutics, SL develops therapies for cancers with limited treatment options, with founders Salvador Benitah and Valerie Vanhooren (CEO) leading the company. In June 2026 it raised EUR 74.2 million in Series B funding co-led by Columbus Venture Partners and Merieux Equity Partners, with Cofides and Korys also participating. Its pipeline includes an ADC for refractory breast cancer and a monoclonal antibody targeting CD36.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in